Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antibiotic, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. It also provides contract research and manufacturing services. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Marksans Pharma Limited

Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-counter drugs, as well as active pharmaceutical ingredients and finished dosage forms for cardiovascular, central nervous system, gastroenterology, anti-allergies, anti-diabetics, anti-retroviral, antibiotics, dermatology, respiratory, and oncology. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, inhalers, transdermal patches, vaccines, topicals, and depot injections. The company also exports its products. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine for India and UNICEF. Aurobindo Pharma Limited was incorporated in 1986 and is headquartered in Hyderabad, India.

Aurobindo Pharma Limited

Marksans Pharma is a pharmaceutical company involved in the formulation, manufacturing, and marketing of finished dosage pharmaceutical formulations, with a global footprint.

Metric
Company Name	Marksans Pharma Limited	Aurobindo Pharma Limited
Symbol	MARKSANS	AUROPHARMA
MSH ID	COM:MARKSANSPHARMA	COM:AUROBINDO
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Drug Manufacturers - General	Drug Manufacturers - Specialty & Generic
Country	IN	IN
Stage
Employee Count	852	23.45K
Website	marksanspharma.com	aurobindo.com
LinkedIn
Founders

Metric
Market Cap	1.03B	9.12B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	257.07M	3.42B
Revenue (LTM)
Revenue (NTM)
Gross Profit	91.07M	1.29B
EBITDA	54.14M	689.83M
Operating Income	45.37M	510.18M
Net Income	37.04M	374.60M
EPS	0.08	0.64
Diluted EPS	0.08	0.64
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.52	0.55
Operating Profit Margin	0.20	0.17
EBITDA Margin	0.21	0.20
Net Profit Margin	0.15	0.12
Return on Equity	0.24	0.14
Return on Assets	0.12	0.08
Return on Capital Employed	0.19	0.15

COM:MARKSANSPHARMA

Marksans Pharma

Last Close

308.65

25/11 09:40

Market Cap

87.17B

Beta: -

Volume Today

1.20M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	22.85	25.84
P/B Ratio	3.61	2.13
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	6.36	3.11
EV Multiple	29.20	13.82

Metric
Days Sales Outstanding	82.40	63.94
Days Payables Outstanding	74.71	134.46
Days Inventory Outstanding	198.04	256.02
Operating Cycle	274.00	317.31
Cash Conversion Cycle	188.03	201.05
Asset Turnover	0.85	0.66

Metric
Operating Cash Flow	30.24M	290.99M
Free Cash Flow	5.58M	-129.49M
Cash Flow to Debt	0.55	0.47
Operating Cash Flow/Sales	0.06	0.11
Free Cash Flow Yield		-0.00

Metric
Cash & Equivalents	79.52M	741.22M
Accounts Receivable	-4.39M	-31.19M
Inventory	72.96M	1.16B
Goodwill	4.66M	70.26M
Debt to Capitalization	0.11	0.18
Debt to Assets	0.05	0.15
Current Ratio	5.12	1.81
Quick Ratio	3.19	1.18

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		-0.00
R&D to Revenue
SG&A to Revenue